Successful control of heavily pretreated metastatic gastric cancer with the mTOR inhibitor everolimus (RAD001) in a patient with PIK3CA mutation and pS6 overexpression

BACKGROUND: Everolimus (RAD001) is an orally administered mTOR inhibitor that is well known for its antitumor efficacy and that has been approved for the treatment of several solid tumors, including renal cell carcinoma. In gastric cancer (GC), despite previous preclinical and phase I/II studies sug...

Descrición completa

Gardado en:
Detalles Bibliográficos
Publicado en:BMC Cancer
Main Authors: Park, Ji Hyun, Ryu, Min-Hee, Park, Young Soo, Park, Sook Ryun, Na, Young-Soon, Rhoo, Baek-Yeol, Kang, Yoon-Koo
Formato: Artigo
Idioma:Inglês
Publicado: BioMed Central 2015
Assuntos:
Case Report
Acceso en liña:https://ncbi.nlm.nih.gov/pmc/articles/PMC4374284/
https://ncbi.nlm.nih.gov/pubmed/25886409
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s12885-015-1139-7
Tags: Engadir etiqueta
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!

Títulos similares